Article

An Efficient Synthesis of Novel Dispirooxindole Derivatives via One-Pot Three-Component 1,3-Dipolar Cycloaddition Reactions

Zhibin Huang [1,†], Qian Zhao [2,†], Gang Chen [3], Huiyuan Wang [1], Wei Lin [1], Lexing Xu [4], Hongtao Liu [4], Juxian Wang [4], Daqing Shi [1,*] and Yucheng Wang [4,*]

[1] Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
[2] Tianjin ShuiGe Hospital, Tianjin 300120, China
[3] Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory, Xinchang 312500, China
[4] Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

[†] These authors contributed equally to this work.

[*] Authors to whom correspondence should be addressed; E-Mails: dqshi@suda.edu.cn (D.S.); wyc9999@126.com (Y.W.); Tel.: +86-512-6588-0049 (D.S.); Fax: +86-512-6588-0089 (D.S.); Tel./Fax: +86-010-6316-5263 (Y.W.).

Abstract: A series of novel dispirooxindoles have been synthesized through three-component 1,3-dipolar cycloaddition of azomethine ylides generated *in situ* by the decarboxylative condensation of isatin and an *α*-amino acid with the dipolarophile 5-benzylidene-1,3-dimethylpyrimidine-2,4,6-trione. This method has the advantages of mild reaction conditions, high atom economy, excellent yields, and high regio- and stereo-selectivity.

Keywords: dispirooxindole; three-component reaction; 1,3-dipolar cycloaddition; azomethine ylide

1. Introduction

In recent decades, multicomponent reactions (MCRs) have emerged as a powerful synthetic strategy due to their efficiency, atom economy, high selectivity and convenience in the construction of multiple new bonds, which permit a rapid access to combinatorial libraries of complex organic molecules for efficient lead structure identification and optimization in drug discovery [1–4]. According to this method, the products are formed in a single step and diversity can be achieved simply by varying the reacting components.

1,3-Dipolar cycloaddition of azomethine ylides with olefinic and acetylenic dipolarophiles has gained significance as it proceeds with high regiochemical and stereochemical selectivity yielding pyrroline and pyrrolidine derivatives [5–7], which are prevalent in a variety of biologically active compounds [8] and are also inhibitors of many diseases such as diabetes [9], cancer [10] and viral infections [11]. Because of their remarkable biological activities, significant efforts have been devoted to the synthesis of their novel derivatives.

Among the various nitrogen-containing heterocycles, functionalized pyrrolidine, pyrrolizidine and oxindole alkaloids have become important synthetic targets as they constitute classes of compounds with significant biological activity [12]. The synthesis of spiro compounds has drawn considerable attention of chemists as have their highly pronounced biological properties [13,14]. The spirooxindole system as the core structure of many pharmacological agents and natural alkaloids [15–18], and has potent nonpeptide p53-MDM2 inhibitory activity [19]. Elacomine, spirotryprostatins A and B are some of the alkaloids containing spiropyrrolidinyloxindole ring systems. Some spiropyrrolidines are potential antileukaemic and anticonvulsant agents [20] and possess antiviral and local anaesthetic activities [21].

Barbituric acid has widely been used in the manufacture of plastics [22], textiles [23], polymers [24] and pharmaceuticals [25–28]. Barbiturates (derivatives of barbituric acid) like pentobarbital and phenobarbital were long used as anxiolytics and hypnotics. Spirobarbiturates are a class of compounds with interesting pharmacological and physiological activity [29–31]. We have recently reported the regio- and stereoselective synthesis of novel dispirooxindole derivatives via multicomponent reactions [32–36]. To expand our research program which aims to synthesize new spiro compounds and nitrogen heterocycles with biological activities, we report herein, the efficient synthesis of a series of novel dispirooxindole derivatives in excellent yields by the three-component 1,3-dipolar cycloaddition reaction of nonstabilized azomethine ylides generated *in situ* by the decarboxylative condensation of isatin and *α*-amino acids with 5-benzylidene-1,3-dimethylpyrimidine-2,4,6-trione using ethanol under reflux conditions.

2. Results and Discussion

In an effort to optimize this process, the three-component reaction of isatin (**1**), sarcosine (**2**), and the dipolarophile 5-(4-bromobenzylidene)-1,3-dimethylpyrimidine-2,4,6-trione (**3a**) was carried out in various solvents under reflux conditions as a simple model reaction in order to determine the best reaction solvent (Scheme 1). The results are summarized in Table 1. As can be seen from the data, the reaction could be efficiently carried out in solvents such as ethanol, methanol, acetonitrile, THF and

1,4-dioxane. In particular, the reaction using ethanol as the solvent resulted in higher yields and shorter reaction times than those using methanol, acetonitrile, THF and 1,4-dioxane. Thus, ethanol, which is a low cost bio-renewable product with low toxicity to human health and is relatively non-hazardous to the environment was chosen as the solvent for all further reactions (Table 1, entry 1) [37].

Scheme 1. The model reaction.

Table 1. Optimization of solvent effect on the model reaction [a].

Entry	Solvent	Time (h)	Yield [b] (%)
1	Ethanol	2	84
2	Methanol	2	56
3	Acetonitrile	3	75
4	Tetrahydrofuran (THF)	6	80
5	1,4-Dioxane	8	60

[a] Reaction conditions: isatin (0.5 mmol), sarcosine (0.5 mmol) and 5-(4-bromobenzylidene)-1,3-dimethylpyrimidine-2,4,6-trione (0.5 mmol) in solvent (10 mL) at reflux temperature; [b] Yields of isolated products.

Using the optimized reaction conditions, various structurally diverse 5-benzylidene-1,3-dimethyl-pyrimidine-2,4,6-triones were investigated (Table 2). It was found that the aromatic rings bearing either electron-withdrawing or electron-donating functional groups were suitable for the reaction, while the cycloaddition reactions with dipolarophiles carrying electron-donating substituents required a longer times and the yield decreased (Table 2, entry 2).

Table 2. Synthesis of dispirooxindole derivatives **4** via three-component reaction.

Entry	Product	Ar	Time (h)	Yield (%)
1	**4a**	$4\text{-BrC}_6\text{H}_4$	2	84
2	**4b**	$4\text{-CH}_3\text{C}_6\text{H}_4$	2.5	75
3	**4c**	$4\text{-NO}_2\text{C}_6\text{H}_4$	1.5	90
4	**4d**	$4\text{-ClC}_6\text{H}_4$	2	88

In order to establish the scope of this cycloaddition reaction, we extended the same protocol using istain (**1**), L-thioproline (**5**) and dipolarophiles **3** under the same reaction conditions to give a series of cycloadducts **6** in excellent yields (Table 3).

Table 3. Synthesis of dispirooxindole derivatives **6** via three-component reactions.

| Entry	Product	Ar	Time (h)	Yield (%)
1	**6a**	$4\text{-}BrC_6H_4$	1	84
2	**6b**	$4\text{-}CH_3C_6H_4$	2	81
3	**6c**	$4\text{-}NO_2C_6H_4$	1	87
4	**6d**	$4\text{-}ClC_6H_4$	1	83
5	**6e**	C_6H_5	1	82
6	**6f**	$2\text{-}NO_2C_6H_4$	1.5	82
7	**6g**	$3,4\text{-}Cl_2C_6H_3$	1.5	88
8	**6h**	Thiophen-2-yl	3	86

With the use of Discrete Fourier Transformation (DFT) and the B3LYP/6-31G computer programme [38], a geometrical optimization of product **4a** was obtained and is shown in Figure 1. From Figure 1, we found that the geometry **A** (*trans*) was more stable than geometry B (*cis*) ($\Delta E = 10.98$ kJ/mol).

Figure 1. Optimized geometry of **4a**.

geometry **A** (E = −3979.727957 hartree).

Figure 1. *Cont.*

geometry **B** (E = −3979.723775 hartree).

To expand the scope of the current method, acenaphthenequinone (**7**) was examined as a replacement for isatin (**1**). The desired products **8** were obtained under the optimized conditions. The results are summarized in Table 4.

Table 4. Synthesis of dispirooxindole derivatives **8** via three-component reaction.


Entry	Product	Ar	Time (h)	Yield (%)
1	**8a**	C_6H_5	1	82
2	**8b**	$3,4\text{-}Cl_3C_6H_3$	1.5	80
3	**8c**	$3,4\text{-}OCH_2OC_6H_3$	3	78

The structures of the products were identified by IR, ^{1}H-NMR, ^{13}C-NMR and HRMS spectra. The structure and regiochemistry of the products were assigned on the basis of their spectroscopic analysis. For example, in the ^{1}H-NMR spectrum of compound **4c**, a sharp singlet at δ 2.13 due to the N-methyl protons was seen. The benzylic proton exhibited a doublet of doublets at δ 3.71 (*J* = 10.4 Hz and 8.0 Hz). The off resonance decoupled ^{13}C-NMR spectrum added conclusive support. The ^{13}C-NMR spectrum of **5c** showed peaks at δ 81.17 and δ 67.26 for the two spirocarbons, respectively. The mass spectrum of **4c** showed a molecular ion peak at *m/z* 486.1392 (M+Na). The X-ray crystallographic study of single of **8b** (Figure 2) not only confirmed the structure deduced from NMR spectroscopic studies, but also determined the stereochemical outcome of the cycloaddition.

Figure 2. X-Ray crystal structure of compound **8b**.

Although the detailed mechanism of the above reaction has not been elucidated yet, the formation of **4** can be explained by the mechanism proposed in Scheme 2. The reaction proceeds through the generation of azomethine ylide (dipole **7**) via the condensation of isatin (**1**) with sarcosine (**2**) and decarboxylation. The dipolarophile **3** regioselectively reacts with azomethine ylides (dipole **7**) in ethanol to give the desired products dispiro compounds **4** (Scheme 2, path A). The cycloaddition proceeds via an *endo* transition state [39–41]. The regioselectivity in the product formation can be explained by considering the secondary orbital interaction (SOI) [42,43] of the orbital of the carbonyl group of dipolarophile **3** with those of the ylide **7** as shown in Scheme 2. In this transition state, these orbital interactions are typically orthogonal in nature and occur between the oxygen atom of the carbonyl of the isatin and the carbon atom of the carbonyl of the dipolarophile **3**. Accordingly, the observed regioisomer **4** via path A is more favorable because of the SOI which is not possible in path B.

Scheme 2. Proposed reaction mechanism for the formation of compound **4**.

3. Experimental

3.1. General

All reagents were purchased from commercial sources and used without further purification. Melting points are uncorrected. IR spectra were recorded on a Nicolet 6700 spectrometer in KBr with absorptions in cm^{-1}. ^{1}H-NMR spectra were determined on a Varian Inova-300/400 MHz spectrometer in DMSO-d_6 solution. *J* values are in Hz. Chemical shifts are expressed in ppm downfield from internal standard TMS. HRMS data were obtained using Bruker micrOTOF-Q instrument or TOF-MS instrument. The starting compounds **3** were prepared according to the previously reported procedures [44,45].

3.2. General Procedure for the Synthesis of Dispirooxindoles 4, 6 and 8

A dry 50 mL flask was charged with isatin (**1**) or acenaphthenequinone (**7**) (0.5 mmol), sarcosine (**2**) or L-thioproline (**5**) (0.5 mmol), dipolarophile **3** (0.5 mmol) and ethanol (10 mL). The mixture was stirred at reflux temperature for 1–3 h. After completion of the reaction (monitored by TLC), the solvent was removed under vacuum. The solid was recrystallized from ethanol, and then dried at 80 °C for 4h under vacuum to give compounds **4**, **6** or **8**.

2,7,9-Trimethyl-4-(4-bromophenyl)-1-(spiro-3'-indolino)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**4a**). White solid; m.p. 180–182 °C; IR (KBr, cm^{-1}): 3313, 2939, 1735, 1679, 1618, 1468, 1420, 1374, 1070, 753; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.12 (s, 3H, CH$_3$), 2.88–2.89 (m, 6H, 2 × CH$_3$), 3.60 (m, 1H, CH$_2$), 3.89 (t, *J* = 8.0 Hz, 1H, CH$_2$), 5.18 (t, *J* = 8.8 Hz, 1H, CH), 6.78 (d, *J* = 7.6 Hz, 1H, ArH), 6.82 (d, *J* = 7.2 Hz, 1H, ArH), 6.96 (t, *J* = 6.4 Hz, 1H, ArH), 7.13–7.15 (m, 2H, ArH), 7.26 (t, *J* = 6.8 Hz, 1H, ArH), 7.41 (d, *J* = 8.4 Hz, 2H, ArH), 10.51 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 28.52, 29.67, 35.92, 41.98, 56.60, 67.26, 81.17, 110.42, 112.85, 120.15, 122.12, 123.59, 125.16, 131.02, 131.56, 137.96, 143.70, 150.33, 164.76, 166.92, 175.70; HRMS: calculated for C$_{23}$H$_{21}$^{79}BrN$_4$O$_4$Na [M+Na]$^+$: 519.0638, found: 519.0621.

2,7,9-Trimethyl-4-(4-methylphenyl)-1-(spiro-3'-indolino)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**4b**). White solid; m.p. 190–191 °C; IR (KBr, cm^{-1}): 3321, 2949, 1735, 1689, 1672, 1515, 1471, 1373, 752; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.13 (s, 3H, CH$_3$), 2.23 (s, 3H, CH$_3$), 2.90 (s, 6H, 2 × CH$_3$), 3.56–3.60 (m, 1H, CH$_2$), 3.91 (t, *J* = 9.2 Hz, 1H, CH$_2$), 5.19 (t, *J* =9.2 Hz, 1H, CH), 6.76–6.78 (m, 1H, ArH), 6.82–6.84 (m, 1H, ArH), 6.96 (t, *J* = 7.2 Hz, 1H, ArH), 7.04 (s, 4H, ArH), 7.26 (t, *J* = 7.6 Hz, 1H, ArH), 10.49 (s, 1H, NH); ^{13}C-NMR (100 MHz, DMSO-d_6): δ (ppm) 21.17, 28.47, 29.61, 35.91, 42.26, 56.84, 67.33, 81.08, 110.36, 122.09, 123.73, 125.09, 128.43, 129.37, 131.63, 135.38, 135.93, 143.66, 150.33, 164.77, 167.02, 175.77; HRMS: calculated for C$_{24}$H$_{24}$N$_4$O$_4$[M]$^+$: 432.1792, found: 432.1800.

2,7,9-Trimethyl-4-(4-nitrophenyl)-1-(spiro-3'-indolino)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**4c**). White solid; m.p. 188–190 °C; IR (KBr, cm^{-1}): 3350, 2926, 1730, 1684, 1619, 1599, 1520, 1469, 1379, 1348, 754; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.13 (s, 3H, CH$_3$), 2.90 (s, 6H, 2 × CH$_3$), 3.71 (dd, *J$_1$* = 8.0 Hz, *J$_2$* = 10.4 Hz, 1H, CH$_2$), 3.93 (t, *J* = 8.0 Hz, 1H, CH$_2$), 5.30 (t, *J* = 9.2 Hz, 1H, CH),

6.78–6.84 (m, 2H, ArH), 6.97 (t, J = 7.6 Hz, 1H, ArH), 7.28 (t, J = 8.0 Hz, 1H, ArH), 7.44 (d, J = 8.8 Hz, 2H, ArH), 8.08 (d, J = 8.8 Hz, 2H, ArH), 10.57 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 30.51, 31.670, 37.85, 44.31, 58.50, 69.16, 83.07, 112.41, 124.11, 125.34, 125.67, 127.20, 131.77, 133.77, 145.70, 148.45, 148.98, 152.31, 166.77, 168.80, 177.57; HRMS: calculated for $C_{23}H_{21}N_5O_6Na$ [M+Na]$^+$: 486.1384, found: 486.1392.

2,7,9-Trimethyl-4-(4-chlorophenyl)-1-(spiro-3'-indolino)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**4d**). White solid; m.p. 240–242 °C; IR (KBr, cm^{-1}): 3317, 2926, 1736, 1718, 1679, 1620, 1570, 1468, 1379, 758; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.89 (s, 3H, CH$_3$), 2.90 (s, 3H, CH$_3$), 3.08 (s, 3H, CH$_3$), 3.61 (dd, J_1 = 8.4 Hz, J_2 = 10.0 Hz, 1H, CH$_2$), 3.89 (t, J = 8.0 Hz, 1H, CH$_2$), 5.20 (t, J = 9.2 Hz, 1H, CH), 6.78 (d, J = 8.0 Hz, 1H, ArH), 6.82–6.84 (m, 1H, ArH), 6.96 (t, J = 7.6 Hz, 1H, ArH), 7.19–7.21 (m, 1H, ArH), 7.29 (d, J = 8.4 Hz, 3H, ArH), 7.33–7.35 (m, 1H, ArH), 10.52 (s, 1H, NH); ^{13}C-NMR (100 MHz, DMSO-d_6): δ (ppm) 28.53, 29.67, 35.93, 41.97, 56.69, 67.34, 81.18, 110.42, 122.13, 123.62, 125.17, 128.66, 130.63, 131.63, 131.72, 137.55, 143.72, 150.53, 164.78, 166.94, 175.70; HRMS: calculated for $C_{23}H_{21}{}^{35}ClN_4O_4$ [M]$^+$: 452.1251, found: 452.1260.

1,3-Dimethyl-5'-(4-bromophenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6a**). White solid; m.p. 194–196 °C; IR (KBr, cm^{-1}): 3236, 2926, 1741, 1719, 1679, 1615, 1469, 1376, 749; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.94 (s, 3H, CH$_3$), 3.05–3.08 (m, 1H, CH$_2$), 3.28–3.33 (m, 2H, CH$_2$), 3.40–3.42 (m, 4H, CH$_3$ and CH), 3.79 (d, J = 10.4 Hz, CH), 4.29 (d, J = 10.0 Hz, 1H, CH$_2$), 4.96–5.00 (m, 1H, CH$_2$), 6.82 (d, J = 7.2 Hz, 1H, ArH), 6.98–7.02 (m, 1H, ArH), 7.29 (t, J = 7.2 Hz, 1H, ArH), 7.39–7.41 (m, 2H, ArH), 7.46–7.48 (m, 2H, ArH), 7.61 (d, J = 7.2 Hz, 1H, ArH), 10.84 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 33.93, 34.09, 42.24, 55.22, 58.79, 76.38, 76.57, 85.45, 115.22, 125.77, 126.48, 127.08, 135.10, 136.20, 136.30, 137.28, 140.40, 147.07, 155.71, 169.89, 171.56, 180.61; HRMS: calculated for $C_{24}H_{22}{}^{79}BrN_4O_4S$ [M+H]$^+$: 541.0540, found: 541.0559.

1,3-Dimethyl-5'-(4-methylphenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6b**). White solid; m.p. 188–190 °C; IR (KBr, cm^{-1}): 3213, 2921, 1740, 1684, 1620, 1472, 1369, 752; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.24 (s, 3H, CH$_3$), 2.52 (s, 3H, CH$_3$), 2.95 (s, 3H, CH$_3$), 3.02 (dd, J_1 = 3.2 Hz, J_2 = 11.2 Hz, 1H, CH$_2$), 3.31–3.33 (m, 1H, CH$_2$), 3.38–3.40 (m, 1H, CH), 3.78–3.81 (m, 1H, CH), 4.28–4.31 (m, 1H, CH$_2$), 4.98–5.03 (m, 1H, CH$_2$), 6.82 (d, J = 7.6 Hz, 1H, ArH), 7.00 (t, J = 7.6 Hz, 1H, ArH), 7.07–7.09 (m, 2H, ArH), 7.27–7.32 (m, 3H, ArH), 7.61 (d, J = 7.6 Hz, 1H, ArH), 10.76 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 25.95, 33.90, 34.10, 42.45, 55.63, 58.78, 76.57, 76.63, 85.40, 115.26, 126.45, 127.13, 134.11, 134.72, 135.12, 136.13, 137.83, 141.50, 147.05, 155.68, 169.81, 171.56, 180.65; HRMS: calculated for $C_{25}H_{25}N_4O_4S$ [M]$^+$: 477.1591, found: 477.1607.

1,3-Dimethyl-5'-(4-nitrophenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6c**). White solid; m.p. 186–188 °C; IR (KBr, cm^{-1}): 3205, 3086, 2952, 1741, 1683, 1522, 1419, 1348, 749; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.94 (s, 3H, CH$_3$), 3.14–3.17 (m, 2H, CH$_2$), 3.41 (s, 4H, CH$_3$ and CH), 3.79 (d, J = 10.0 Hz, 1H, CH), 4.46–4.48 (m, 1H, CH$_2$), 5.02 (s, 1H, CH$_2$), 6.82–6.84 (m, 1H, ArH), 7.00–7.02 (m, 1H, ArH), 7.28–7.30 (m, 1H, ArH),

7.61–7.62 (m, 1H, ArH), 7.68–7.70 (m, 2H, ArH), 8.11–8.13 (m, 2H, ArH), 10.86 (s, 1H, NH); ^{13}C-NMR (100 MHz, DMSO-d_6): δ (ppm) 29.21, 29.39, 37.49, 50.57, 53.77, 71.59, 72.13, 80.60, 121.79, 122.27, 123.58, 130.29, 131.38, 131.53, 142.33, 144.55, 146.96, 150.95, 165.20, 166.83, 175.71; HRMS: calculated for $C_{24}H_{22}N_5O_6S$ [M+H]$^+$: 508.1285, found: 508.1290.

1,3-Dimethyl-5'-(4-chlorophenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6d**). White solid; m.p. 162–164 °C; IR (KBr, cm^{-1}): 3289, 3062, 2908, 1751, 1733, 1680, 1496, 1376, 755; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.87 (s, 3H, CH$_3$), 2.89 (s, 3H, CH$_3$), 3.18 (t, *J* = 9.6 Hz, 1H, CH$_2$), 3.25–3.29 (m, 1H, CH$_2$), 3.42 (d, *J* = 7.6 Hz, 1H, CH), 3.72 (d, *J* = 7.6 Hz, 1H, CH), 4.70–4.74 (m, 1H, CH$_2$), 4.83–4.85 (m, 1H, CH$_2$), 6.77–6.79 (m, 1H, ArH), 6.94–7.01 (m, 2H, ArH), 7.25–7.29 (m, 1H, ArH), 7.32–7.34 (m, 4H, ArH), 10.71 (s, 1H, NH); HRMS: calculated for $C_{24}H_{21}{}^{35}ClN_4O_4SNa$ [M+Na]$^+$: 519.0864, found: 519.0871.

1,3-Dimethyl-5'-phenyl-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo[1,2-c] thiazole]-2,4,6-trione (**6e**). White solid; m.p. 183–184 °C; IR (KBr, cm^{-1}): 3212, 3082, 2953, 1740, 1680, 1615, 1472, 1367, 754; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.53 (s, 3H, CH$_3$), 2.96 (s, 3H, CH$_3$), 3.07 (dd, J_1 = 3.6 Hz, J_2 = 11.2 Hz, 1H, CH$_2$), 3.33–3.35 (m, 1H, CH$_2$), 3.39 (d, *J* = 10.0 Hz, 1H, CH), 3.80 (d, *J* = 10.4 Hz, 1H, CH), 4.36 (d, *J* = 10.0 Hz, 1H, CH$_2$), 4.99–5.04 (m, 1H, CH$_2$), 6.83 (d, *J* = 7.6 Hz, 1H, ArH), 7.01 (t, *J* = 7.6 Hz, 1H, ArH), 7.19–7.23 (m, 1H, ArH), 7.26–7.31 (m, 3H, ArH), 7.40–7.42 (m, 2H, ArH), 7.61 (d, *J* = 7.6 Hz, 1H, ArH), 10.77 (s, 1H, NH); ^{13}C-NMR (100 MHz, DMSO-d_6): δ (ppm) 34.27, 34.46, 42.90, 56.16, 59.00, 76.97, 85.73, 115.54, 126.83, 127.51, 132.64, 133.88, 135.04, 135.50, 136.49, 141.47, 147.38, 156.06, 170.16, 171.94, 180.97; HRMS: calculated for $C_{24}H_{23}N_4O_4S$ [M+H]$^+$: 463.1435, found: 463.1443.

1,3-Dimethyl-5'-(2-nitrophenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6f**). White solid; m.p. 184–186 °C; IR (KBr, cm^{-1}): 3220, 2947, 1743, 1685, 1616, 1536, 1471, 1370, 782, 763; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.34 (s, 3H, CH$_3$), 2.97 (s, 3H, CH$_3$), 3.00 (s, 1H, CH$_2$), 3.04 (s, 1H, CH$_2$), 3.10–3.14 (m, 1H, CH), 3.82 (d, *J* =10.8 Hz, 1H, CH), 4.88–4.90 (m, 1H, CH$_2$), 5.07–5.11 (m, 1H, CH$_2$), 6.81–6.83 (m, 1H, ArH), 7.01 (t, *J* = 7.6 Hz, 1H, ArH), 7.29 (t, *J* =7.6 Hz, 1H, ArH), 7.50 (t, *J* =8.0 Hz, 1H, ArH), 7.59 (d, *J* = 7.6 Hz, 1H, ArH), 7.68 (t, *J* = 8.0 Hz, 1H, ArH), 7.78 (d, *J* = 7.6 Hz, 1H, ArH), 8.36 (d, *J* = 8.0 Hz, 1H, ArH), 10.84 (s, 1H, NH); HRMS: calculated for $C_{24}H_{22}N_5O_6S$ [M+H]$^+$: 508.1285, found: 508.1296.

1,3-Dimethyl-5'-(3,4-dichlorophenyl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo[1,2-c]thiazole]-2,4,6-trione (**6g**). White solid; m.p. 192–194 °C; IR (KBr, cm^{-1}): 3074, 2957, 1757, 1721, 1688, 1614, 1469, 1367, 748; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.46 (s, 3H, CH$_3$), 2.94 (s, 3H, CH$_3$), 3.03 (dd, J_1 = 2.4 Hz, J_2 = 11.2 Hz, 1H, CH$_2$), 3.23–3.28 (m, 1H, CH$_2$), 3.40 (s, 1H, CH), 3.78 (d, *J* = 10.8 Hz, 1H, CH), 4.27 (d, *J* = 10.0 Hz, 1H, CH$_2$), 4.99–5.04 (m, 1H, CH$_2$), 6.83 (d, *J* = 7.6 Hz, 1H, ArH), 7.00 (t, *J* = 7.6 Hz, 1H, ArH), 7.30 (t, *J* = 7.6 Hz, 1H, ArH), 7.49–7.56 (m, 2H, ArH), 7.63 (d, *J* = 7.6 Hz, 1H, ArH), 7.71 (s, 1H, ArH), 10.84 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 28.69, 35.78, 43.32, 57.18, 67.90, 84.56, 120.35, 122.04, 122.14, 127.39, 128.96, 129.47, 130.19, 130.47, 130.92, 131.70, 132.97, 133.13, 137.67, 142.05, 149.92, 164.77, 167.07, 203.16; HRMS: calculated for $C_{24}H_{21}{}^{35}Cl_2N_4O_4S$ [M+H]$^+$: 531.0655, found: 531.0674.

1,3-Dimethyl-5'-(thiophen-2-yl)-7'-(spiro-3''-indolino)tetrahydro-1H,1'H-spiro[pyrimidine-5,6'-pyrrolo [1,2-c]thiazole]-2,4,6-trione (**6h**). White solid; m.p. 164–166 °C; IR (KBr, cm^{-1}): 3243, 3078, 2956, 1738, 1679, 1568, 1439, 1382; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.88 (s, 3H, CH$_3$), 2.92 (s, 3H, CH$_3$), 3.12–3.17 (m, 2H, CH$_2$), 3.44 (d, *J* = 7.6 Hz, 1H, CH), 3.70 (d, *J* = 7.2 Hz, 1H, CH), 4.72–4.76 (m, 1H, CH$_2$), 5.05 (d, *J* = 8.4 Hz, 1H, CH$_2$), 6.79 (d, *J* = 7.6 Hz, 1H, ArH), 6.92–7.00 (m, 4H, ArH), 7.25–7.29 (m, 1H, ArH), 7.37–7.38 (m, 1H, ArH), 10.74 (s, 1H, NH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 28.68, 29.70, 36.56, 43.83, 51.33, 73.06, 74.23, 79.44, 110.74, 122.54, 124.32, 125.06, 126.02, 127.49, 127.69, 132.03, 138.48, 142.86, 150.04, 164.75, 165.76, 176.46; HRMS: calculated for C$_{22}$H$_{21}$N$_4$O$_4$S$_2$ [M+H]$^+$: 469.0999, found: 469.0980.

2,7,9-Trimethyl-4-phenyl-1-(spiro-2'-acenaphthylenone)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**8a**). White solid; m.p. 168–170 °C; IR (KBr, cm^{-1}): 3063, 2920, 1748, 1723, 1685, 1442, 1371, 833, 783, 751; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.19 (s, 6H, 2 × CH$_3$), 2.91 (s, 3H, CH$_3$), 3.83 (t, *J* = 8.0 Hz, 1H, CH$_2$), 4.08 (t, *J* = 8.0 Hz, 1H, CH$_2$), 5.18 (t, *J* = 8.0 Hz, 1H, CH), 7.16 (s, 3H, ArH), 7.25 (s, 2H, ArH), 7.30 (d, *J* = 8.0 Hz, 1H, ArH), 7.72 (s, 1H, ArH), 7.82–7.88 (m, 2H, ArH), 8.04–8.06 (m, 1H, ArH), 8.29–8.31 (m, 1H, ArH); ^{13}C-NMR (100 MHz, DMSO-d_6): δ (ppm) 33.40, 33.45, 40.51, 48.79, 62.13, 72.64, 89.12, 126.78, 126.80, 131.85, 132.07, 133.12, 133.68, 133.70, 134.19, 135.06, 135.22, 137.60, 138.01, 143.03, 146.74, 154.67, 169.55, 171.95, 207.93; HRMS: calculated for C$_{27}$H$_{23}$N$_3$O$_4$Na [M+Na]$^+$: 476.1581, found: 476.1582.

2,7,9-Trimethyl-4-(3,4-dichlorophenyl)-1-(spiro-2'-acenaphthylenone)-2,7,9-triazaspiro[4.5]decane-6,8,10-trione (**8b**). White solid; m.p. 192–194 °C; IR (KBr, cm^{-1}): 2965, 1721, 1684, 1640, 1372, 783, 750; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.12 (s, 3H, CH$_3$), 2.17 (s, 3H, CH$_3$), 2.89 (s, 3H, CH$_3$), 3.79 (t, *J* = 8.0 Hz, 1H, CH$_2$), 4.05 (t, *J* = 8.0 Hz, 1H, CH$_2$), 5.15 (t, *J* = 7.6 Hz, 1H, CH), 7.17–7.19 (m, 1H, ArH), 7.28–7.30 (m, 1H, ArH), 7.46–7.51 (m, 2H, ArH), 7.71–7.75 (m, 1H, ArH), 7.83–7.90 (m, 2H, ArH), 8.07 (d, *J* = 8.0 Hz, 1H, ArH), 8.32 (d, *J* = 7.2 Hz, 1H, ArH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 28.66, 35.73, 42.82, 56.93, 56.95, 68.00, 84.70, 120.77, 122.08, 122.15, 127.42, 128.89, 129.44, 129.99, 130.07, 130.42, 130.70, 131.09, 131.22, 131.39, 133.01, 139.12, 142.07, 149.89, 164.73, 166.92, 203.09; HRMS: calculated for C$_{27}$H$_{21}$Cl$_2$N$_3$O$_4$Na [M+Na]$^+$: 509.1113, found: 509.1338.

2,7,9-Trimethyl-4-(3,4-methylenedioxylphenyl)-1-(spiro-2'-acenaphthylenone)-2,7,9-triazaspiro[4.5] decane-6,8,10-trione (**8c**). White solid; m.p. 186–188 °C; IR (KBr, cm^{-1}): 2939, 2897, 1730, 1692, 1500, 1364, 1233, 832, 783; ^{1}H-NMR (400 MHz, DMSO-d_6): δ (ppm) 2.16 (s, 6H, 2 × CH$_3$), 2.91 (s, 3H, CH$_3$), 3.73 (s, 1H, CH$_2$), 4.02 (s, 1H, CH$_2$), 5.10 (s, 1H, CH), 5.96 (s, 2H, CH$_2$), 6.64 (s, 1H, ArH), 6.77–6.82 (m, 2H, ArH), 7.30 (s, 1H, ArH), 7.72–7.87 (m, 3H, ArH), 8.05 (s, 1H, ArH), 8.30 (s, 1H, ArH); ^{13}C-NMR (75 MHz, DMSO-d_6): δ (ppm) 27.39, 34.47, 42.72, 56.19, 67.02, 83.22, 100.23, 107.34, 108.13, 120.73, 120.89, 126.02, 127.68, 128.15, 129.06, 129.20, 130.11, 131.55, 132.06, 140.67, 145.25, 146.47, 148.62, 163.47, 165.86, 201.87; HRMS: calculated for C$_{28}$H$_{23}$N$_3$O$_6$ [M]$^+$: 497.1587, found: 497.1585.

3.3. X-ray Crystallography [46]

The single-crystals of compound **8b** were obtained by slow evaporation from ethanol. Intensity data were collected on a Bruker P4 diffractometer with graphite monochromated Mo Kα radiation (λ = 0.71073 Å) using the ω scan mode with 1.34º < θ < 25.02º; 4188 unique reflections were measured and 3254 reflections with $I > 2\sigma(I)$ were used in the Fourier techniques. The final refinement was converged to R = 0.0428 and wR = 0.1266. Crystal data for **8b**: empirical formula $C_{27}H_{21}Cl_2N_3O_4$, crystal dimension 0.42 × 0.40 × 0.37 mm, triclinic, space group P-1, a = 8.0847(7) Å, b = 10.0554(10) Å, c = 15.5500(13) Å, α = 76.8210(10)º, β = 86.626(2)º, γ = 76.2960(10)º, V = 1195.79(19)Å^3, Mr = 522.37, Z = 2, Dc = 1.451 Mg/m^3, μ(Mo Kα) = 0.312 mm^{-1}, $F(000)$ = 540, S = 1.079.

4. Conclusions

In summary, we have successfully developed a 1,3-dipolar cycloaddition of azomethine ylides, and a series of novel dispiro cycloadducts were obtained. This method has the advantages of convenient operation, mild reaction conditions, short reaction time, and high efficiency.

References and Notes

1. Dömling, A.; Ugi, I. Multicomponent Reactions with Isocyanides. *Angew. Chem. Int. Ed. Engl.* **2000**, *39*, 3168–3210.
2. Dömling, A. Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry. *Chem. Rev.* **2006**, *106*, 17–89.
3. Zhu, J.; Bienaymé, H. *Multicomponent Reactions*; Wiley-VCH: Weinheim, Germany, 2005.
4. Dou, G.L.; Shi, C.L.; Shi, D.Q. Highly Regioselective Synthesis of Polysubstituted Pyrroles through Three-Component Reaction Induced by Low-Valent Titanium Reagent. *J. Comb. Chem.* **2008**, *10*, 810–813.
5. Dondas, H.A.; Fishwick, C.W.G.; Grigg, R.; Kilner, C. 1,3-Dipolar cycloaddition of stabilised and non-stabilised azomethine ylides derived from uracil polyoxin C (UPoC): Access to nikkomycin analogues. *Tetrahedron* **2004**, *60*, 3473–3485.
6. Boruah, M.; Konwar, D.; Sharma, S.D. KF/Al$_2$O$_3$ mediated 1,3-dipolar cycloaddition of azomethine ylides: A novel and convenient procedure for the synthesis of highly substituted pyrrolidines. *Tetrahedron Lett.* **2007**, *48*, 4535–4537.

7. Kawashima, K.; Kakehi, A.; Noguchi, M. Generation of functionalized azomethine ylides and their application to stereoselective heterocycle synthesis: An equivalent process of C-unsubstituted nitrile ylide cycloaddition reaction. *Tetrahedron* **2007**, *63*, 1630–1643.

8. Watson, A.A.; Flett, G.W.J.; Asano, N.; Molyneux, R.J.; Nash, R.J. Polyhydroxylated alkaloids-natural occurrence and therapeutic applications. *Phytochemistry* **2001**, *56*, 265–295.

9. Horri, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. *J. Med. Chem.* **1986**, *29*, 1038–1046.

10. Spearman, M.A.; Jamieson, J.C.; Wright, J.A. Studies on the effect of glycoprotein processing inhibitors on fusion of L6 nyoblast cell lines. *Exp. Cell Res*. **1987**, *168*, 116–126.

11. Karpas, A.; Fleet, G.W.J.; Dwek, R.A.; Petursson, S.; Namgoong, S.K.; Pamsden, N.G.; Jacob, G.S.; Rademacher, T.W. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 9229–9233.

12. Alcaide, B.; Almendros, P.; Alonso, J.M.; Aly, M.F. Rapid and Stereocontrolled Synthesis of Racemic and Optically Highly Functionalized Pyrrolidine Systems via Rearrangement of 1,3-Dipolar Cycloadducts Derived from 2-Azetidinone-Tethered Azomethine Ylides. *J. Org. Chem.* **2001**, *66*, 1351–1358.

13. Kobayashi, J.; Tsuda, M.; Agemi, K.; Shigemori, H.; Ishibashi, M.; Sasaki, T.; Mikami, Y. Purealidines B and C, new bromotyrosine alkaloids from the okinawan marine sponge *psammaplysilla purea. Tetrahedron* **1991**, *47*, 6617–6622.

14. James, D.M.; Kunze, H.B.; Faulkner, D.J. Two New Brominated Tyrosine Derivatives from the Sponge Druinella (=Psammaplysilla) purpurea. *J. Nat. Prod*. **1991**, *54*, 1137–1140.

15. Dandia, A.; Singh, R.; Khaturia, S.; Merienne, C.; Morgant, G.; Loupy, A. Efficient microwave enhanced regioselective synthesis of a series of benzimidazolyl/triazolyl spiro[indole-thiazolidinones] as potent antifungal agents and crystal structure of spiro[3*H*-indole-3,2'-thiazolidine]-3'(1,2,4-triazol-3-yl)-2,4'(1*H*)-dione. *Bioorg. Med. Chem.* **2006**, *14*, 2409–2417.

16. Sebahar, P.R.; Williams, R.M. The Asymmetric Total Synthesis of (+)- and (−)-Spirotryprostatin B. *J. Am. Chem. Soc*. **2000**, *122*, 5666–5667.

17. Ma, J.; Hecht, S.M. Javaniside, a novel DNA cleavage agent from *Alangium javanicum* having a unusual oxindole skeleton. *Chem. Commun*. **2004**, 1190–1191.

18. Kang, T.H.; Matsumoto, K.; Tohda, M.; Murakami, Y.; Takayama, H.; Kitajima, M.; Aimi, N.; Watanabe, H. Pteropodine and isopteropodine positively modulate the function of rat muscarinic M_1 and 5-HT$_2$ receptors expressed in *Xenopus oocyte. Eur. J. Pharmacol.* **2002**, *444*, 39–45.

19. Ding, K.; Lu, Y.; Coleska, N.Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Tomita, Y.; *et al*. Structure-Based Design of Potent Non-Peptide MDMZ Inhibitors. *J. Am. Chem. Soc*. **2005**, *127*, 10130–10131.

20. Abou-Gharbia, M.A.; Doukas, P.H. Synthesis of Tricyclic Arylspiro Compounds as Potential Antileukemic and Anticonvulsant Agents. *Heterocycles* **1979**, *12*, 637–640.

21. Kornet, M.J.; Thio, A.P. Oxindole-3-spiropyrrolidines and -piperidines. Synthesis and local anesthetic activity. *J. Med. Chem.* **1976**, *19*, 892–898.

22. Thetford, D.; Chorlton, A.P.; Hardman, J. Synthesis and properties of some polycyclic barbiturate pigments. *Dyes Pigments* **2003**, *59*, 185–191.

23. Bartzatt, R. Determination of barbituric acid, utilizing a rapid and simple colorimetric assay. *J. Pharm. Biomed. Anal.* **2002**, *29*, 909–915.

24. Andreu, R.; Garin, J.; Orduna, J.; Alcala, R.; Villacampa, B. Novel NLO-phores with Proaromatic Donor and Acceptor Groups. *Org. Lett.* **2003**, *5*, 3143–3146.

25. Meusel, M.; Ambrozak, A.; Hecker, T.K.; Gutschow, M. The Aminobarbituric Acid-Hydrantoin Rearrangement. *J. Org. Chem.* **2003**, *68*, 4684–4692.

26. Brunner, H.; Ittner, K.P.; Lunz, D.; Schmatloch, S.; Schmidt, T.; Zabel, M. Highly Enriched Mixtures of Methohexital Stereoisomers by Palladium-Catalyzed Allylation and Their Anaesthetic Activity. *Eur. J. Org. Chem.* **2003**, *5*, 855–862.

27. Neumann, D.M.; Jursic, B.S.; Martin, K.L. Preparation of 5-(cyclohexylmethyl)barbituric acid derivatives by acid-catalyzed reductive cyclohexylmethylation of barbituric acids with *p*-hydroxy or *p*-methoxybenzaldehydes. *Tetrahedron Lett.* **2002**, *43*, 1603–1606.

28. Jursic, B.S.; Neumann, D.M. Preparation of 5-formyl- and 5-acetylbarbituric acids, including the corresponding Schiff bases and phenylhydrazones. *Tetrahedron Lett.* **2001**, *42*, 8435–8439.

29. Galati, E.M.; Monforte, M.T.; Miceli, N.; Raneri, E. Anticonvulsant and sedative effects of some 5-substituted bromopyrazolinic spirobarbiturates. *Farmaco* **2001**, *56*, 459–461.

30. Singh, P.; Paul, K. A practical approach for spiro- and 5-monoalkylated barbituric acid. *J. Heterocycl. Chem.* **2006**, *43*, 607–612.

31. Lomlm, L.; Einsiedel, J.; Heinemann, F.W.; Meyer, K.; Gmeiner, P. Proline Derived Spirobarbiturates as Highly Effective *β*-Turn Mimetics Incorporating Polar and Functionalizable Constraint Elements. *J. Org. Chem.* **2008**, *73*, 3608–3611.

32. Liu, H.; Dou, G.L.; Shi, D.Q. Regio- and Stereoselective Synthesis of Novel Spiropyrrolidine Bioxindole Derivatives via Multicomponent Reactions. *J. Comb. Chem.* **2010**, *12*, 292–294.

33. Liu, H.; Dou, G.L.; Shi, D.Q. Regioselective Synthesis of Novel Spiropyrrolidines and Spirothiapyrrolizidines Through Multicomponent 1,3-Dipolar Cycloaddition Reaction of Azomethin Ylides. *J. Comb. Chem.* **2010**, *12*, 633–637.

34. Chen, H.; Shi, D.Q. Efficient one-pot synthesis of spiro[indoline-3,4'-pyrazolo[3,4-e][1,4]thiazepine]dione via three-component reaction. *Tetrahedron* **2011**, *67*, 5686–5692.

35. Hu, Y.; Zou, Y.; Wu, H.; Shi, D.Q. A facile and efficient ultrasound-assisted synthesis of novel dispiroheterocycles through 1,3-dipolar cycloaddition reactions. *Ultrason. Sonochem.* **2012**, *19*, 264–269.

36. Liu, H.; Zou, Y.; Hu, Y.; Shi, D.Q. An Efficient One-Pot Synthesis of Dispiropyrrolidine Derivatives Through 1,3-Dipolar Cycloaddition Reactions Under Ultrasound Irradiation. *J. Heterocycl. Chem.* **2011**, *48*, 877–881.

37. Capello, C.; Fischer, U.; Hungerbühler, K. What is a green solvent? A comprehensive framework for the environmental assessment of solvents. *Green Chem.* **2007**, *9*, 927–934.

38. We have calculated possible configurations of the products at the DFT level of theory, and all the calculations were performed at the B3LYP/6-31G level of theory. First, the geometrical optimizations of the two possible configurations were obtained, and then the lowest energy minimum corresponds to the configurations were calculated. All calculations were carried out with a Gaussian 09W program package.

39. Ardill, H.; Dorrity, M.J.R.; Grigg, R.; Leon-Ling, M.S.; Malone, J.F.; Sridharan, V.; Thianpatanagul, S. X=Y-ZH compounds as potential 1,3-Dipoles. Part 28, the iminium ion route to azomethine ylides. Background and reaction of amines with bifunctional ketones. *Tetrahedron* **1990**, *46*, 6433–6448.

40. Ardill, H.; Fontaine, X.L.R.; Grigg, R.; Henderson, D.; Montgomery, J.; Sridharan, V.; Surendrakumar, S. X=Y-ZH compounds as potential 1,3-dipoles. Part 29. The iminium ion route to azomethine ylides. Reaction of cyclic secondary amines with mono- and bi-functional aldehydes. *Tetrahedron* **1990**, *46*, 6449–6466.

41. Subramaniyan, G.; Raghunathan, R.; Nethaji, M. A facile entry into a new class of spiroheterocycles: Synthesis of dispiro[oxindolechromanone/flavanone/tetralone]pyrroloiso-quinoline ring systems. *Tetrahedron* **2002**, *58*, 9075–9079.

42. Pardasani, R.T.; Pardasani, P.; Chaturvedi, V.; Yadav, S.K.; Saxena, A.; Sharma, I. Theoretical and synthetic approach to novel spiroheterocycles derived from isatin derivatives and L-proline via 1,3-dipolar cycloaddition. *Heteroat. Chem.* **2003**, *14*, 36–41.

43. Lakshmi, N.V.; Thirumurugan, P.; Perumal, P.T. An expedient approach for the synthesis of dispiropyrrolidine bisoxindoles, spiropyrrolidine oxindoles and spiroindane-1,3-diones through 1,3-dipolar cycloaddition reactions. *Tetrahedron Lett.* **2010**, *51*, 1064–1068.

44. Jursic, B.S.; Neumann, D.M. Reductive C-alkylation of barbituric acid derivatives with carbonyl compounds in the presence of platinum and palladium catalysts. *Tetrahedron Lett.* **2001**, *42*, 4103–4107.

45. Krasnov, K.A.; Kartsev, V.G.; Gorovoi, A.S.; Khrustalev, V.N. Chemical Modification of Plant Alkaloids. III. X-Ray Diffraction and NMR Studies of the Structure of 1,3-Dimethyl-5-arylmethyl-5-cytisylmethylbarbituric Acids. *Chem. Nat. Compd.* **2002**, *38*, 450–457.

46. Crystallographic data for **8b** have been deposited at the Cambridge Crystallographic Data Centre with the deposition number CCDC906792. Copies of these data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB 2 1EZ, UK; Fax: +44-1223-336-033; or E-Mail: deposit@ccdc.cam.ac.uk).

Sample Availability: Samples of the compounds **4** and **6** are available from the authors.